Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-420 in Transfusion-dependent β-Thalassemia
NCT02274233Phase 1Terminated
- Sponsor
- Sideris Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of petadeferitrin in iron overload (6 arms), sponsored by Sideris Pharmaceuticals. Primary endpoint: Number of Participants with Adverse Events up to 35 days. Started Oct 2014; status: terminated.
02
Drugs
petadeferitrin
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT02274233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02274233.